EUCTR2013-001632-21-PL进行中（未招募）不适用
A randomized, double-blind, parallel group phase III multi-center trial to compare twice daily topical application of M518101, Daivonex® and vehicle in patients with plaque psoriasis
Maruho Europe Limited0 个研究点目标入组 725 人开始时间: 2013年8月7日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 725
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •All of the following criteria have to be met for inclusion of a patient in this trial:
- •1.Male or female patients aged 18 years or older on the day of signing the ICF;
- •2.Signed and dated ICF obtained prior to any trial related activities;
- •3.Clinical diagnosis of stable plaque psoriasis of at least 6 months duration (involving the trunk, limbs, palms and/or feet);
- •4.Patients who have up to 20% BSA affected with plaques at V1 (screening) and V2 (Wk0-D1) (BSA calculation should not include face/scalp but should include palms of hands and soles of feet);
- •5.Patients who are assessed as moderate or severe in IGA at V1 (screening) and V2 (Wk0-D1) and who are suitable for topical therapy;
- •6.Women of childbearing potential (less than post-menopausal for two years) should have a negative pregnancy test (serum) at V1 (screening);
- •7.Sexually active female patients of childbearing potential (less than post-menopausal for two years), must agree to use documented means of effective birth control (such as oral, transdermal, injectable or implanted hormonal contraceptives; intrauterine device, diaphragm with spermicide, use of a condom by the sexual partner or sterile sexual partner) during the course of the treatment phase; local requirements on contraception are to be followed;
- •8.Patients who have at least one psoriatic plaque (minimum size: 10 cm2 in area) of which PSI total score >= 12 (on trunk, arms or legs) at V1 (screening) and V2 (Wk0-D1);
- •9.Patients who are capable of understanding and willing to give signed informed consent prior to any protocol specific procedure and are able to complete the trial and comply with protocol instructions.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients are to be excluded from the trial, when one or more of the following conditions are met:
- •1.Patients with known allergic reactions, irritations or sensitivity to the active ingredients (history or presence of allergy to vitamin D3 derivatives or presence of relevant drug hypersensitivity) or other components of the investigational products;
- •2.Patients who test positive for HIV Ag/Ab, HBs-Ag or HCV-Ab at V1 (screening);
- •3.Patients 65 years old or older with serum creatinine levels exceeding the upper limit of reference range at V1 (screening);
- •4.Patients who have any renal (serum creatinine level > 1.5 times above the upper limit of reference range) or liver insufficiency (alkaline phosphatase, aspartate aminotransferase, or alanine aminotransferase level > 2.5 fold above upper limit of reference range), or clinically significant cardiac, renal or hepatic disease at V1 (screening);
- •5.Patients, who in the opinion of the investigator, have clinically relevant history or presence of any disease, any other skin disorder, any chronic medical condition which is not well controlled or surgical history which may interfere with the conduct of the trial;
- •6.Patients who, in the opinion of the investigator, are not deemed eligible as determined by medical history, physical examination (including vital signs), ECG, or clinical laboratory safety tests;
- •7.Patients whose calcium test at V1 (screening) exceed the upper limit of reference range (including serum calcium, albumin, phosphate, parathyroid hormone);
- •8.Subjects who have at least one of the three QTcF measurements at screening of > 450 msec as shown on the ECG;
- •9.Patients who have used M5181 (active ingredient of M518101);
- •10.Patients who have used any study drug (including experimental biologics) and/or participated in any clinical trial within the last 60 days before the day of randomization V2 (Wk0-D1);
- •11.Patients who have been treated with any biologics for their psoriasis within 30 days or 5 half-lives (whichever is longer) of the biologic before the day of randomization (V2), the longest documented half-life of the biologic should be used to calculate the 5 half-lives;
- •12.Patients who have been treated with phototherapy (e.g. PUVA, ultraviolet A [UVA], ultraviolet B [UVB]), laser, oral steroids, oral retinoid, oral immunosuppressive/immunomodulative drugs, cytostatics, cyclosporine or methotrexate within 30 days of randomization V2 (Wk0-D1);
- •13.Patients who have been treated with topical steroids, topical immunosuppressive/ immunomodulative drugs, topical vitamin D3 derivative, topical retinoids, anthralin, coal tar (except when used as shampoo, see section 5.4.7) or salicylic acid within 14 days of randomization V2 (Wk0-D1);
- •14.Patients treated with medicines which are known to worsen psoriasis (lithium, beta-blockers and chloroquine), except when the patient is on stable dosing with stable psoriatic condition for more than 12 weeks before the day of randomization and remains on stable dose throughout the trial;
- •15.Patients who are taking oral vitamin D supplement, except when the patients have been on a stable dose (up to 2,000 IU per day allowed) for at least 56 days (8 weeks) before the day of randomization and plan to continue the dose for the duration of the trial;
- •16.Patients taking medicines that affect calcium metabolism (e.g. any oral prescription Vitamin D derivatives, calcium preparations, bisphosphonate, thiazide diuretics or hormone preparation except for oral cont
研究者
相似试验
进行中（未招募）
不适用
A multi-center clinical trial with parallel groups of psoriatic patients receiving different treatments for comparison of a new topical vitamin D3 formulation with the placebo and the marketed comparator Daivonex®MedDRA version: 17.0Level: LLTClassification code 10050576Term: Psoriasis vulgarisSystem Organ Class: 100000004858Plaque psoriasisEUCTR2013-001632-21-HUMaruho Europe Limited725
进行中（未招募）
不适用
A multi-center clinical trial with parallel groups of psoriatic patients receiving different treatments for comparison of a new topical vitamin D3 formulation with the placebo and the marketed comparator Daivonex®MedDRA version: 17.0Level: LLTClassification code 10050576Term: Psoriasis vulgarisSystem Organ Class: 100000004858Plaque psoriasisEUCTR2013-001632-21-LTMaruho Europe Limited725
进行中（未招募）
不适用
A multi-center clinical trial with parallel groups of psoriatic patients receiving different treatments for comparison of a new topical vitamin D3 formulation with the placebo and the marketed comparator Daivonex®Plaque psoriasisEUCTR2013-001632-21-BGMaruho Europe Limited725
进行中（未招募）
不适用
A multi-center clinical trial with parallel groups of psoriatic patients receiving different treatments for comparison of a new topical vitamin D3 formulation with the placebo and the marketed comparator Daivonex®MedDRA version: 16.1Level: LLTClassification code 10050576Term: Psoriasis vulgarisSystem Organ Class: 100000004858Plaque psoriasisEUCTR2013-001632-21-ATMaruho Europe Limited725
进行中（未招募）
1 期
Clinical trial to demonstrate that treatments with GP2015 and Enbrel® are comparable in patients with rheumatoid arthritisModerate to severe active rheumatoid arthritisMedDRA version: 19.1Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2012-002009-23-CZHexal AG366